Notably, these variants are primarily associated with colorectal, pancreatic, and lung cancers, underscoring their clinical significance.<h4>Conclusion</h4>This integrative examination provides mechanistic insightinto how specific KRAS variations may prompt oncogenic activation. This evidence concerns the gene KRAS and lung cancer.